

# Britta Will

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6957560/publications.pdf>

Version: 2024-02-01

87  
papers

3,926  
citations

126858

33  
h-index

128225

60  
g-index

93  
all docs

93  
docs citations

93  
times ranked

7687  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>Asxl1</i> loss cooperates with oncogenic <i>Nras</i> in mice to reprogram the immune microenvironment and drive leukemic transformation. <i>Blood</i> , 2022, 139, 1066-1079.	0.6	24
2	To Degrade or Not to Degrade DNMT3A. <i>Cancer Discovery</i> , 2022, 12, 23-25.	7.7	0
3	Fighting AML with its own weapons. <i>Blood</i> , 2022, 139, 807-809.	0.6	0
4	Effects of eltrombopag on mesenchymal stem cells in immune thrombocytopenia purpura. <i>British Journal of Haematology</i> , 2022, , .	1.2	0
5	Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2022, 14, eabb7695.	5.8	13
6	SEPHguarding acute myeloid leukemia. <i>Cell Stem Cell</i> , 2022, 29, 350-352.	5.2	1
7	High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. <i>Nature Medicine</i> , 2022, 28, 468-471.	15.2	19
8	PU.1-Dependent Enhancer Inhibition Separates <i>Tet2</i> -Deficient Hematopoiesis from Malignant Transformation. <i>Blood Cancer Discovery</i> , 2022, 3, 444-467.	2.6	10
9	Chaperone-mediated autophagy sustains haematopoietic stem-cell function. <i>Nature</i> , 2021, 591, 117-123.	13.7	145
10	Cytoplasmic Labile Iron Accumulates in Aging Stem Cells Perturbing a Key Rheostat for Identity Control. <i>Blood</i> , 2021, 138, 3282-3282.	0.6	1
11	Lenalidomide and Eltrombopag for Treatment in Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Study Combination Clinical Trial. <i>Blood</i> , 2021, 138, 65-65.	0.6	3
12	No keto for AML stem cells!. <i>Blood</i> , 2020, 136, 1219-1221.	0.6	1
13	The thrombopoietin mimetic JNJ-26366821 increases megakaryopoiesis without affecting malignant myeloid proliferation. <i>Leukemia and Lymphoma</i> , 2020, 61, 2453-2465.	0.6	1
14	PU.1-Dependent Enhancer Decommissioning Drives Transformation of <i>Tet2</i> deficient Hematopoietic Stem and Progenitor Cells. <i>Blood</i> , 2020, 136, 40-40.	0.6	54
15	HIV portends a poor prognosis in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2019, 60, 3529-3535.	0.6	15
16	Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. <i>Seminars in Hematology</i> , 2019, 56, 262-278.	1.8	25
17	Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2019, 25, 6976-6985.	3.2	55
18	1029 - IRON HOMEOSTASIS-REGULATORY PATHWAYS IN HEMATOPOIETIC STEM CELLS. <i>Experimental Hematology</i> , 2019, 76, S37.	0.2	1

#	ARTICLE	IF	CITATIONS
19	Proteome-wide analysis of chaperone-mediated autophagy targeting motifs. <i>PLoS Biology</i> , 2019, 17, e3000301.	2.6	136
20	Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. <i>Blood Advances</i> , 2019, 3, 3962-3967.	2.5	12
21	Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. <i>Nature Medicine</i> , 2019, 25, 103-110.	15.2	169
22	SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML. <i>Blood</i> , 2019, 134, 4224-4224.	0.6	12
23	Clinical ALK5 Inhibitor, Vactosertib, Reverses TGF $\beta$ -1 Stimulated Smad-2 Driven Ineffective Hematopoiesis in MDS. <i>Blood</i> , 2019, 134, 2990-2990.	0.6	3
24	A novel thrombopoietin mimetic RWJ-800088 increases megakaryopoiesis without causing malignant proliferation in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2019, 37, e18527-e18527.	0.8	0
25	High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster. <i>Blood</i> , 2019, 134, 3720-3720.	0.6	1
26	Chaperone-Mediated Autophagy Ensures Hematopoietic Stem Cell Maintenance. <i>Blood</i> , 2019, 134, 272-272.	0.6	0
27	Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling. <i>Blood</i> , 2019, 134, 1280-1280.	0.6	0
28	Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	187
29	LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBP $\beta$ -dependent enhancers in AML. <i>Blood</i> , 2018, 131, 1730-1742.	0.6	92
30	Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	48
31	Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. <i>Journal of Clinical Investigation</i> , 2018, 128, 5479-5488.	3.9	68
32	Therapeutic Targeting of the Ubiquitin Conjugating Enzyme UBE2N in Myeloid Malignancies. <i>Blood</i> , 2018, 132, 4050-4050.	0.6	0
33	A myeloid tumor suppressor role for NOL3. <i>Journal of Experimental Medicine</i> , 2017, 214, 753-771.	4.2	8
34	Stem and progenitor cell alterations in myelodysplastic syndromes. <i>Blood</i> , 2017, 129, 1586-1594.	0.6	93
35	Dual inhibition of HDMX and HDM2 in acute myeloid leukemia. <i>Experimental Hematology</i> , 2017, 53, S46.	0.2	0
36	Inhibition of the myeloid master regulator PU.1 as a therapeutic strategy in acute myeloid leukemia. <i>Experimental Hematology</i> , 2017, 53, S133.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/ $\beta$ -Catenin Activation. <i>Cancer Research</i> , 2017, 77, 4846-4857.	0.4	61
38	Pharmacological inhibition of the transcription factor PU.1 in leukemia. <i>Journal of Clinical Investigation</i> , 2017, 127, 4297-4313.	3.9	89
39	Direct Pharmacological Inhibition of the Transcription Factor PU.1 in Acute Myeloid Leukemia. <i>Blood</i> , 2017, 130, 858-858.	0.6	0
40	Dual Inhibition of Mdmx and Mdm2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia. <i>Blood</i> , 2017, 130, 795-795.	0.6	4
41	Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. <i>Nature Cell Biology</i> , 2016, 18, 607-618.	4.6	519
42	The PRO-inflammatory cytokine interleukin-1 is a key regulator of hematopoietic Stem cell fate and function. <i>Experimental Hematology</i> , 2016, 44, S49.	0.2	0
43	Leukemic Stem Cells S(p)liced Off. <i>Cell Stem Cell</i> , 2016, 19, 561-563.	5.2	0
44	Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies. <i>Leukemia</i> , 2016, 30, 536-544.	3.3	43
45	Targeting MDS and AML Stem Cells with AZD-9150 Mediated Inhibition of STAT3. <i>Blood</i> , 2016, 128, 4314-4314.	0.6	2
46	HIV Is Associated with a High Rate of Unexplained Multilineage Cytopenias and Portends a Poor Prognosis in Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 4345-4345.	0.6	4
47	Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS-Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109. <i>Blood</i> , 2016, 128, 2749-2749.	0.6	0
48	IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. <i>Blood</i> , 2015, 125, 3144-3152.	0.6	149
49	New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. <i>Nature Chemical Biology</i> , 2015, 11, 878-886.	3.9	151
50	Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia. <i>Nature Medicine</i> , 2015, 21, 1172-1181.	15.2	112
51	New Allosteric Inhibitors of Mutant IDH1 in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 787-787.	0.6	1
52	Interleukin-1 Drives Precocious Myeloid Differentiation of Hematopoietic Stem Cells at the Expense of Self-Renewal. <i>Blood</i> , 2015, 126, 778-778.	0.6	0
53	Minimal Reduction of PU.1 Is Sufficient to Induce a Preleukemic State and Promote Development of Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 305-305.	0.6	1
54	Stem cell fate regulation by dynein motor protein Lis1. <i>Nature Genetics</i> , 2014, 46, 217-218.	9.4	5

#	ARTICLE	IF	CITATIONS
55	Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone. <i>Leukemia and Lymphoma</i> , 2014, 55, 2901-2906.	0.6	11
56	Combinatorial Haplo-Deficient Tumor Suppression in 7q-Deficient Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2014, 25, 555-557.	7.7	8
57	Stem cell origin of myelodysplastic syndromes. <i>Oncogene</i> , 2014, 33, 5139-5150.	2.6	38
58	Regulation of hematopoietic stem cell fate by special at-rich sequence binding protein 1. <i>Experimental Hematology</i> , 2014, 42, S66.	0.2	0
59	HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2014, 124, 1158-1167.	3.9	38
60	Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine. <i>Blood</i> , 2014, 124, 3602-3602.	0.6	6
61	Myelodysplastic Syndrome Marrow Stroma Shows Widespread Aberrant Hypermethylation That Is Abrogated By Treatment with Dnmt Inhibitors. <i>Blood</i> , 2014, 124, 4379-4379.	0.6	2
62	Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. <i>Nature Immunology</i> , 2013, 14, 437-445.	7.0	92
63	Methylome Profiling Reveals Distinct Alterations in Phenotypic and Mutational Subgroups of Myeloproliferative Neoplasms. <i>Cancer Research</i> , 2013, 73, 1076-1085.	0.4	50
64	Molecular and Functional Characterization Of The Novel Protein-Coding Gene Tihl (Translocated in Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.6	0
65	H2.0-Like Homeobox (HLX) Causes Pre-Leukemic Myeloid Expansion and Initiates AML In Cooperation With FLT3-ITD. <i>Blood</i> , 2013, 122, 4201-4201.	0.6	0
66	A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. <i>Journal of Experimental Medicine</i> , 2012, 209, 35-50.	4.2	67
67	Germline Deletion of <i>Igh</i> Regulatory Region Elements hs 5, 6, 7 (hs5-7) Affects B Cell-Specific Regulation, Rearrangement, and Insulation of the <i>Igh</i> Locus. <i>Journal of Immunology</i> , 2012, 188, 2556-2566.	0.4	42
68	Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. <i>Blood</i> , 2012, 120, 2076-2086.	0.6	181
69	Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. <i>Blood</i> , 2012, 120, 1290-1298.	0.6	165
70	Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. <i>Blood</i> , 2012, 120, 386-394.	0.6	146
71	H2.0-like Homeobox Regulates Early Hematopoiesis and Promotes Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2012, 22, 194-208.	7.7	39
72	Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPβ. <i>Journal of Clinical Investigation</i> , 2012, 122, 2955-2966.	3.9	55

#	ARTICLE	IF	CITATIONS
73	Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML. <i>Blood</i> , 2012, 120, 1875-1875.	0.6	0
74	H2.0-Like Homeobox (HLX) Induces Unlimited Clonogenicity, Blocks Differentiation, and Cooperates with FLT3-ITD in the Induction of Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 651-651.	0.6	0
75	A Large Gene Network in Immature Erythroid Cells Is Controlled by the Myeloid and B Cell Transcriptional Regulator PU.1. <i>PLoS Genetics</i> , 2011, 7, e1001392.	1.5	40
76	Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. <i>Blood</i> , 2010, 115, 2901-2909.	0.6	46
77	Neuronal cell death during metamorphosis of <i>Hydractina echinata</i> (Cnidaria, Hydrozoa). <i>Invertebrate Neuroscience</i> , 2010, 10, 77-91.	1.8	35
78	An organizing region in metamorphosing hydrozoan planula larvae - stimulation of axis formation in both larval and in adult tissue. <i>International Journal of Developmental Biology</i> , 2010, 54, 795-802.	0.3	21
79	Multi-parameter fluorescence-activated cell sorting and analysis of stem and progenitor cells in myeloid malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 391-401.	0.7	36
80	NF- $\kappa$ B overexpression delays erythroid maturation and increases erythrocyte production. <i>British Journal of Haematology</i> , 2009, 146, 203-217.	1.2	22
81	Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Blood</i> , 2009, 114, 3899-3908.	0.6	119
82	PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element. <i>Genes and Development</i> , 2008, 22, 2085-2092.	2.7	169
83	JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling. <i>Experimental Hematology</i> , 2007, 35, 1695-1703.	0.2	32
84	A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2007, 117, 2611-2620.	3.9	109
85	NF-E2 Overexpression Delays Erythroid Differentiation and Increases Erythrocyte Production. <i>Blood</i> , 2007, 110, 1546-1546.	0.6	0
86	A Distal Single Nucleotide Polymorphism Disrupts Development-Dependent Long-Range Transcriptional Regulation of the PU.1 Gene through the Chromatin-Remodeling Protein SATB1 in Acute Myeloid Leukemia. <i>Blood</i> , 2007, 110, 3175-3175.	0.6	0
87	The Transcription Factor Nf-E2 Is Overexpressed in Patients with Polycythemia Vera. <i>Blood</i> , 2004, 104, 659-659.	0.6	13